Analyst David Risinger of Leerink Partners reiterated a Buy rating on Centessa Pharmaceuticals (CNTA – Research Report), retaining the price target of $36.00.
David Risinger has given his Buy rating due to a combination of factors including Centessa Pharmaceuticals’ promising orexin pipeline and solid financial position. The company has reported significant progress in its orexin programs, with Phase 2a data for their lead program, ORX750, expected in 2025 for conditions like narcolepsy and idiopathic hypersomnia. Additionally, their second-generation candidate, ORX142, is advancing through IND-enabling studies, and clinical data are anticipated in 2025.
Furthermore, Centessa’s financial health is robust, with approximately $482 million in cash and equivalents as of the end of 2024, which is expected to sustain operations until mid-2027. Despite a one-time R&D charge due to the discontinuation of their hemophilia program, the company’s strategic focus on its orexin pipeline positions it well for future growth. These factors, along with a raised price target, underpin Risinger’s optimistic outlook on the stock.
In another report released on March 24, BMO Capital also maintained a Buy rating on the stock with a $35.00 price target.